Next Article in Journal
A Systematic Review and Meta-Analysis of Mobile Devices and Weight Loss with an Intervention Content Analysis
Next Article in Special Issue
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
Previous Article in Journal / Special Issue
Differential Transcriptome Profile of Peripheral White Cells to Identify Biomarkers Involved in Oxaliplatin Induced Neuropathy
Article Menu

Export Article

Open AccessReview
J. Pers. Med. 2014, 4(3), 297-310; doi:10.3390/jpm4030297

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

Department of Chest Medicine, Taipei Veteran General Hospital, Yang-Min National University, No. 21, Sec. 2, Shi-Pai Rd., Taipei 11217, Taiwan
*
Author to whom correspondence should be addressed.
Received: 27 March 2014 / Revised: 15 April 2014 / Accepted: 4 June 2014 / Published: 25 June 2014
(This article belongs to the Special Issue Personalized Cancer Therapy)
View Full-Text   |   Download PDF [464 KB, uploaded 26 June 2014]

Abstract

In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonine at position 790 (T790M), which has accounted for more than half of the cases, developed inevitably in patients who were previously treated with EGFR-TKI. At present, there is no standard treatment for patients who have developed a resistance to EGFR-TKI. Several strategies have been developed or suggested to treat such patients. This article aimsto review the EGFR-TKI re-treatment strategy and the efficacy of different generations of EGFR-TKIs in patients with acquired resistance to prior EGFR-TKI. View Full-Text
Keywords: epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI); non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI); non-small cell lung cancer (NSCLC)
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wu, W.-S.; Chen, Y.-M. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J. Pers. Med. 2014, 4, 297-310.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top